A Rare Case of Thrombotic Thrombocytopenic Purpura (TTP) With Concurrent Renal Cell Carcinoma: Diagnostic and Therapeutic Challenges.

Autor: Bhandari A; Internal Medicine, St John's Hospital, Springfield, USA., Pokhrel B; Intensive Care Unit, Hospital for Advanced Medicine and Surgery, Kathmandu, NPL., Oli PR; Internal Medicine, Province Hospital, Surkhet, NPL., Le Q; Hospital Medicine, University of Missouri School of Medicine, Columbia, USA., Basnet B; Internal Medicine, Frye Regional Medical Center, Hickory, USA., Freitag EC; Pathology and Laboratory Medicine, St. John's Hospital, Springfield, USA., Nayani A; Hematology and Oncology, Springfield Clinic, Springfield, USA.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2023 May 25; Vol. 15 (5), pp. e39494. Date of Electronic Publication: 2023 May 25 (Print Publication: 2023).
DOI: 10.7759/cureus.39494
Abstrakt: Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening thrombotic microangiopathy (TMA) that needs prompt identification and treatment. Disseminated malignancy-related TMA can potentially be misdiagnosed as TTP, and patients may be inappropriately subjected to therapeutic plasma exchange (TPE) with serious implications. Likewise, the presence of a concurrent cancer diagnosis in a patient with microangiopathic hemolytic anemia and thrombocytopenia may lead to suspicion of disseminated malignancy as the cause, delaying the TPE with serious outcomes. Testing for ADAMTS13 activity is diagnostic of TTP, but the results may take time. This poses a diagnostic and therapeutic dilemma that includes weighing the benefits of TPE for treating TTP and cancer treatment. We describe a rare case of immune-mediated TTP in a patient concurrently diagnosed with metastatic renal cell cancer. To our knowledge, this is the first case of TTP reported in patients with metastatic renal cell carcinoma (RCC) in a non-treatment-naive patient.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Bhandari et al.)
Databáze: MEDLINE